Platinum is named as an intervention in 10 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). The most-studied condition is Esophageal Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
NCT03731442 · ClinicalTrials.gov ↗ · Esophageal Cancer
|
Phase 3 | Recruiting | Chinese Academy of Medical Sciences | China |
|
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
NCT05735145 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy
|
Phase 3 | Recruiting | Fourth Affiliated Hospital of Guangxi Medical University | China |
|
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy
|
Phase 2 | Recruiting | Peking Union Medical College | China |
|
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
NCT06151743 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Carcinoma
|
Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | China |
|
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287 · ClinicalTrials.gov ↗ · Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel
|
Phase 1/2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
|
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
NCT06951841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
|
Phase 4 | Not yet open | China Medical University, China | China |
|
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
NCT07097948 · ClinicalTrials.gov ↗ · Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation
|
Phase 2 | Not yet open | Shanghai Pulmonary Hospital, Shanghai, China | China |
|
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
NCT07497074 · ClinicalTrials.gov ↗ · Cervical Cancer
|
Phase 2 | Not yet open | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | China |
|
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
NCT07510594 · ClinicalTrials.gov ↗ · Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma
|
Phase 2 | Not yet open | Tianjin Medical University Cancer Institute and Hospital | China |
|
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150 · ClinicalTrials.gov ↗ · SCLC
|
Phase 2 | Active, closed | Biotheus Inc. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Esophageal Cancer | 2 |
| Chemoradiotherapy | 2 |
| Albumin-bound Paxlitaxel | 1 |
| Unresectable Malignant Neoplasm | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Postoperative Incidental Small Cell Lung Cancer | 1 |
| Toripalimab Adjuvant Therapy Evaluation | 1 |
| Large-Cell Neuroendocrine Carcinoma of the Lung | 1 |
| Extrapulmonary Neuroendocrine Carcinoma | 1 |
| Cervical Cancer | 1 |
| Small Cell Lung Cancer | 1 |
| SCLC | 1 |
| Uterine Cervical Neoplasms | 1 |
| Adjuvant Chemotherapy | 1 |
| Locally Advanced Hypopharyngeal Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Peking Union Medical College | 1 |
| Shanghai Pulmonary Hospital, Shanghai, China | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 1 |
| China Medical University, China | 1 |
| Biotheus Inc. | 1 |
| Fourth Affiliated Hospital of Guangxi Medical University | 1 |
| Chinese Academy of Medical Sciences | 1 |
| Eye & ENT Hospital of Fudan University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 10 | 5 |
A trial with sites in more than one country appears in each of those registers.
10 current trials in our China register name Platinum as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 10 trials are recruiting: 5 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1), Peking Union Medical College (1), Shanghai Pulmonary Hospital, Shanghai, China (1) and Tianjin Medical University Cancer Institute and Hospital (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Platinum works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Platinum works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Platinum (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.